Accuray Incorporated ARAY

Company Overview

Accuray Incorporated is a U.S.-based medical technology company focused on radiation oncology solutions for the treatment of cancer and certain neurological conditions. The company develops, manufactures, sells, and supports advanced radiation therapy systems designed to deliver highly precise tumor targeting while minimizing exposure to surrounding healthy tissue. Accuray operates primarily within the medical device and oncology technology industries, with revenue generated through the sale of treatment systems, software, service contracts, upgrades, and related consumables.

The company’s principal product platforms are the CyberKnife robotic radiosurgery system and the Radixact and TomoTherapy radiation therapy systems. These technologies are used by hospitals, cancer centers, and specialty treatment clinics globally. Accuray’s competitive positioning centers on precision treatment delivery, adaptive radiation therapy capabilities, integrated imaging, and robotic motion tracking technologies. Founded in 1990 as a spinout connected to research conducted at Stanford University, the company initially focused on stereotactic radiosurgery innovation before expanding into broader radiation therapy solutions through product development and acquisitions, including the acquisition of TomoTherapy Incorporated in 2011.

Business Operations

Accuray generates revenue through two primary areas: product sales and recurring service revenue. Product revenue includes sales of radiation treatment systems, software applications, installation services, and system upgrades. Service revenue includes maintenance agreements, training, parts replacement, and long-term support contracts. The company operates globally through direct sales channels and third-party distributors, with a significant presence in North America, Europe, and Asia-Pacific markets. International markets account for a substantial portion of system installations and order activity.

The company’s core operating platforms include the CyberKnife system, which uses robotic radiosurgery and real-time imaging for highly targeted treatments, and the Radixact platform, which integrates helical delivery and adaptive therapy capabilities. Accuray also provides oncology software solutions designed to improve treatment planning and workflow efficiency. The company maintains strategic relationships with hospitals, academic medical centers, distributors, and clinical research institutions. Manufacturing operations and technology development are concentrated primarily in the United States, while sales and support infrastructure extend across multiple international markets.

Strategic Position & Investments

Accuray’s strategic direction has focused on expanding adoption of precision radiation therapy technologies, increasing recurring service revenue, and strengthening its software-driven treatment ecosystem. The company has invested in adaptive radiation therapy capabilities, treatment planning software enhancements, and workflow automation intended to improve clinical efficiency and patient outcomes. Product innovation initiatives have emphasized real-time motion synchronization, AI-assisted treatment planning features, and integrated imaging technologies.

The acquisition of TomoTherapy Incorporated significantly expanded Accuray’s portfolio and positioned the company more competitively within the broader radiation oncology market. Accuray has also pursued partnerships with healthcare institutions and distributors to broaden geographic reach and accelerate installation growth in emerging markets. The company continues to target opportunities in hypofractionated treatment, stereotactic body radiation therapy, and adaptive oncology solutions, which are viewed as growing segments within radiation medicine. Public filings and investor materials indicate ongoing investment in software platforms and system upgrades intended to extend the usable life and clinical functionality of installed systems.

Geographic Footprint

Accuray is headquartered in Madison, Wisconsin, with operational, commercial, and support activities spanning multiple regions worldwide. The company maintains a strong presence in North America, while also operating extensively across Europe and the Asia-Pacific region. China and other Asian markets have represented important growth opportunities due to expanding oncology infrastructure and increasing demand for advanced radiation treatment technologies.

The company supports customers in more than 50 countries through a combination of direct operations and distributor partnerships. International revenue and order activity form a meaningful component of overall business performance. Accuray’s systems are installed in academic medical centers, community hospitals, and specialized cancer treatment facilities globally, giving the company operational exposure across developed and emerging healthcare markets.

Leadership & Governance

Accuray operates under a corporate governance structure led by executive management and a board of directors responsible for strategic oversight, operational execution, and long-term capital allocation. Leadership communications and public filings have consistently emphasized innovation in radiation oncology, global market expansion, operational efficiency, and customer support as central strategic priorities.

Key executives include:

• Suzanne Winter – President and Chief Executive Officer
• Shigeyuki Hamamatsu – Senior Vice President and Chief Financial Officer
• Todd Powell – Senior Vice President and Chief Commercial Officer
• Daphné Sartsilmazian – Senior Vice President, Chief Marketing Officer and International Business Operations
• Sharon Levita – Senior Vice President, Chief Legal Officer and Corporate Secretary

The company’s leadership strategy has emphasized expanding clinical adoption of precision therapy technologies, strengthening recurring service revenue streams, and advancing product innovation through research, software integration, and global commercial partnerships.